AbbVie to present new data from HCV study

|About: AbbVie Inc. (ABBV)|By:, SA News Editor

Later today, AbbVie (ABBV -1.3%) will present more data from PEARL-1, the Phase 2b study of ABT-450/r — a collaborative effort with Enanta Pharmaceuticals (ENTA -0.2%) — in combination with ABT-267.

95% of GT-1b treatment-naïve patients and 90% of prior null responders achieved SVR12. (PR)

More on recent developments in new HCV treatments here.